By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss neighbours and cancer leaders Roche. The deal includes two recently approved GSK products for ...

GSK and Pfiz­er have set­tled a law­suit al­leg­ing Pfiz­er’s RSV shot Abrys­vo in­fringed GSK’s patents. A Pfiz­er ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Guidelines from the Advisory Committee on Immunization Practices help physicians decide what vaccines to recommend to patients and are also used for determining insurance coverage in the U.S. The ...

Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot’s success in 2020 until after that year’s election, the Wall Street Journal reported ...

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...

GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. Pfizer denied the allegations and argued GSK's patents ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...